Independent Pharmacy Review In Nsw Workers Compensation

NSW Workers Compensation

If you manage NSW workers compensation claims, you may have come across the term "Section 19 pharmacy review." It is factually incorrect. An independent pharmacy review is commissioned and funded under Section 60 of the Workers Compensation Act 1987, supported by the WIM Act 1998 and the SIRA medication management framework. Getting the framework right is what makes a review defensible in disputes, properly recoverable as a treatment expense, and useful as clinical evidence on the claim file.

Clearing up the "Section 19" misconception

Section 19 of the Workers Compensation Act 1987 (NSW) is titled "Presumptions relating to certain employment." It is a liability-side provision that deems certain diseases, such as brucellosis, Q fever, and leptospirosis, to have been contracted in the course of prescribed employment. It is used in determining whether an illness is work related.

Section 19 confers no authority on SIRA, insurers, or any other body to request, commission, or fund pharmacy reviews. It has no connection to medication assessment, treatment decisions, or claims-side clinical review. If you have seen the term "Section 19 pharmacy review" used in claims discussions or online explainers, it is a misattribution. The framework that actually applies is set out below.

The statutory framework that does apply

Independent pharmacy reviews in NSW workers compensation are commissioned and funded under four instruments that work together.

Section 60 of the Workers Compensation Act 1987. Section 60 governs the insurer's liability for medical, hospital, and rehabilitation expenses. It establishes the test under which an insurer must fund treatment, including independent pharmacy reviews, as part of injury management. The current test is "reasonably necessary" treatment. From 1 July 2026, the test transitions to "reasonable and necessary" under the Workers Compensation Legislation Amendment (Reform and Modernisation) Act 2026, aligning the workers compensation scheme more closely with CTP and the NDIS framework.

Workplace Injury Management and Workers Compensation Act 1998. The WIM Act establishes the broader claims management framework, including insurer obligations around injury management, the use of independent medical examinations, and how clinical evidence is weighed in claim decisions.

SIRA Workers Compensation Guidelines. Made under both Acts, the Guidelines set the operational standards for how claims, treatment decisions, and clinical reviews are conducted across the scheme.

SIRA Medication Management Best Practice Guide (2020). This is the operational benchmark for medication management in NSW workers compensation and CTP schemes. It defines best practice for high-risk medication oversight, opioid prescribing, polypharmacy management, and the role of independent pharmacist-led reviews in supporting safe, evidence-based prescribing.

Together, these instruments authorise insurers to commission independent pharmacy reviews, set the standards by which those reviews should be conducted, and establish the funding pathway. Practical billing is administered through SIRA pharmacy codes.

When to commission an independent pharmacy review

Refer for a pharmacy review when one or more of the following circumstances apply:

• Questions about medication appropriateness or necessity.
• Escalating medication costs without clear clinical justification.
• Dispute about whether medications are claim-related.
• Concern that medications are preventing recovery or contributing to incapacity.
• Long-duration claims with sustained high medication use.
• Polypharmacy, particularly involving high-risk classes such as opioids, benzodiazepines, gabapentinoids, antidepressants, and antipsychotics.
• RTPM data showing multiple prescribers, multiple pharmacies, or dose escalation.
• Pre-IME or pre-dispute preparation where defensible medication evidence is required.
• Medicinal cannabis, ketamine, or other emerging therapies where evidence of indication is required.

What an independent pharmacy review must deliver

For a pharmacy review to support claim decisions, it should meet four standards.

Independence. The reviewing pharmacist must be free of any financial or operational connection to the dispensing of the claimant's medications. A pharmacist reviewing prescriptions for medications they or their employer will dispense has a structural conflict of interest that compromises the review's defensibility.

Expertise. The reviewing pharmacist should have demonstrated clinical experience in workers compensation, CTP, or related personal injury contexts. Generalist clinical pharmacy training is not sufficient for the regulatory and evidentiary requirements of insurance claims.

Comprehensiveness. The review must address every medication the claimant is taking, including over-the-counter products and complementary medicines. It must assess appropriateness, necessity, interactions, dosing, adherence, and alignment with current clinical guidelines.

Defensibility. The review must be evidence-based and grounded in current Australian therapeutic guidelines, TGA approved indications, PBS prescribing requirements, and SIRA's medication management framework. Where the review may be used in dispute, Personal Injury Commission proceedings, or litigation, it must withstand legal scrutiny.

How the process works in practice

A typical independent pharmacy review follows six steps:

1. Referral. The insurer or case manager initiates the referral, providing relevant medical records, prescribing history, and claim context.
2. Pharmacist assignment. An independent, qualified pharmacist is assigned. The claimant is notified of the review, its purpose, and the pharmacist's role.
3. Information gathering. The pharmacist reviews medical and prescribing records, may consult with the claimant directly to obtain history and perception of medication effects, and may liaise with treating prescribers.
4. Clinical assessment. The pharmacist assesses each medication against indication, evidence, dosing, interactions, side effects, alignment with current guidelines, and contribution to recovery or incapacity.
5. Reporting. The pharmacist produces a structured report with findings, recommendations, and a clear evidence trail.
6. Implementation. The insurer and treating providers work with the recommendations to adjust the medication regimen, address dispute matters, or inform funding decisions.

Timing, cost, and acting on findings

A standard independent pharmacy review usually takes 2 to 8 weeks from referral to report, depending on the complexity of the claim and the urgency of the assessment. Where the review is required for urgent safety reasons, faster timelines can be arranged.

The cost of the review is met by the insurer under Section 60 as a "reasonably necessary" treatment-related expense, transitioning to "reasonable and necessary" from 1 July 2026. Pharmacy review costs are billed under specific SIRA pharmacy codes.

Once the report is received, it becomes part of the claim file. Insurers and case managers should:

• Communicate findings to the claimant in plain language.
• Engage treating prescribers on any recommended changes, collaboratively rather than unilaterally.
• Document any changes made or declined, with reasoning.
• Where recommendations are declined by the prescriber, escalate the decision through the medical adviser or IME pathway as appropriate.
• Monitor outcomes to confirm whether recommended changes improved recovery, function, and claim trajectory.

Common outcomes

Pharmacy reviews typically lead to one or more of the following outcomes:

• Confirmation that current medications are appropriate and necessary.
• Dose adjustments to optimise benefit and reduce side effects.
• Substitution of medications for safer or more effective alternatives.
• Deprescribing of medications that are no longer supporting recovery.
• Identification and active management of drug interactions.
• Recommendations for additional monitoring or specialist review.

Framing the review for claimants

Claimants sometimes view pharmacy reviews defensively, particularly if they have been told the review is being arranged because of "high medication costs" or "claim duration." Framing matters. The most constructive framing positions the review as part of the claim's clinical support: "We are arranging a specialist pharmacy review to make sure your medications are working as well as they can, that side effects are being managed, and that your treatment is supporting your recovery." Claimants who understand the review's purpose are more likely to engage openly, which leads to more accurate assessment and better outcomes.

Best practice for claims managers

If you manage NSW workers compensation claims:

• Commission reviews based on clinical indication, not arbitrary thresholds or duration triggers alone.
• Use pharmacists with demonstrated experience in workers compensation and personal injury.
• Provide complete and current information at referral, including medical records, prescribing history, and RTPM data where available.
• Engage with findings constructively, do not file and ignore.
• Document decisions made or declined, with reasoning.
• Track outcomes and feed back into your medication risk management framework.

Key Takeaways

• There is no "Section 19 pharmacy review" in NSW workers compensation. Section 19 deals with disease presumptions, not medication assessment.
• Independent pharmacy reviews are commissioned and funded under Section 60 of the Workers Compensation Act 1987, supported by the WIM Act 1998, the SIRA Workers Compensation Guidelines, and the SIRA Medication Management Best Practice Guide (2020).
• From 1 July 2026, the funding test shifts from "reasonably necessary" to "reasonable and necessary" under the Reform and Modernisation reforms.
• A defensible review must be independent, expert, comprehensive, and evidence-based against current Australian guidelines, TGA indications, and PBS requirements.
• Commission reviews on clinical indication, not cost or duration triggers alone. Reviews run purely to cut costs are clinically poor and legally fragile.

Frequently Asked Questions

Primary source: State Insurance Regulatory Authority (SIRA), Workers Compensation Guidelines and Medication Management Best Practice Guide (2020), www.sira.nsw.gov.au.